Ractigen Therapeutics Advances into Clinical Stage with Groundbreaking saRNA Drug, RAG-01 This milestone marks Ractigen's transition into clinical development, with RAG-01 targeting NMIBC.

Ractigen Presents Preclinical Results of Its saRNA Therapeutic Targeting DMD/BMD at the Oligonucleotide Therapeutics Society (OTS) Annual Meeting Ractigen Presents Preclinical Results of Its saRNA Therapeutic Targeting DMD/BMD at the Oligonucleotide Therapeutics Society (OTS) Annual Meeting

Ractigen Therapeutics Announces the Appointment of Harri Järveläinen as Chief Operating Officer SUZHOU, China, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Ractigen Therapeutics, Inc. announced today that Dr. Harri Järveläinen has been appointed Chief Operating Officer of the Company. "I am thrilled to...